Literature DB >> 8640663

The clinical significance of p53 accumulation in gastric carcinoma.

T Starzynska1, M Markiewski, W Domagala, K Marlicz, J Mietkiewski, S A Roberts, P L Stern.   

Abstract

BACKGROUND: Alterations in the expression of p53 tumor suppressor protein is a frequent event in human cancer but the practical implications of this phenomenon are yet to be fully exploited. The objective of this study was to determine the value of p53 accumulation as a marker of tumor progression and prognosis of gastric carcinoma patients and to evaluate whether this parameter can be properly assessed prior to surgery.
METHODS: The expression of p53 was studied immunohistochemically in 200 gastric carcinomas using paraffin embedded surgical specimens and endoscopic biopsies. The correlation between p53 expression in tumor tissue, selected clinicopathologic variables, and the course of the patients' disease were analyzed.
RESULTS: Results showed that 42.5% of the gastric carcinomas expressed elevated levels of p53 protein. P53 accumulation positivity correlated with increasing tumor stage and size (P < 0.001 and P = 0.025, respectively). P53 positive tumors had a higher propensity for lymph node and distant metastases (P < 0.001). P53 accumulation was also more frequently detected in carcinoma from proximal rather than distal stomach (P = 0.027). In patients receiving potentially curative resection for advanced cancer, p53 accumulation was an independent parameter and the strongest for poor prognosis (RR = 3.7, P < 0.001). There was complete concordance between immunohistochemical detection of p53 in endoscopic and surgical material.
CONCLUSIONS: A preoperative assessment of p53 expression in gastric carcinoma can be helpful to identify patients at high risk of metastatic spread to regional lymph nodes and independently to identify those with especially poor prognosis. When combined with routine procedures, this simple and inexpensive test might allow appropriate planning of better treatment strategies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8640663     DOI: 10.1002/(SICI)1097-0142(19960515)77:10<2005::AID-CNCR7>3.0.CO;2-P

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  The prognostic value of β-catenin and LEF-1 expression in patients with operable gastric carcinoma.

Authors:  Serap Kaya; Mahmut Gumus; Yesim Gurbuz; Devrim Cabuk; Ozgur Acikgoz; Suleyman Temiz; Kazim Uygun
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

2.  Oncogenic role of p53 is suppressed by si-RNA bicistronic construct of uPA, uPAR and cathepsin-B in meningiomas both in vitro and in vivo.

Authors:  Reshu Gupta; Venkateswara Rao Gogineni; Arun Kumar Nalla; Chandramu Chetty; Jeffrey D Klopfenstein; Andrew J Tsung; Sanjeeva Mohanam; Jasti S Rao
Journal:  Int J Oncol       Date:  2011-02-02       Impact factor: 5.650

Review 3.  Gastric adenocarcinoma: review and considerations for future directions.

Authors:  Bryan J Dicken; David L Bigam; Carol Cass; John R Mackey; Anil A Joy; Stewart M Hamilton
Journal:  Ann Surg       Date:  2005-01       Impact factor: 12.969

4.  Potential role and chronology of abnormal expression of the Deleted in Colon Cancer (DCC) and the p53 proteins in the development of gastric cancer.

Authors:  F Graziano; S Cascinu; M P Staccioli; V Catalano; M C Rossi; A M Baldelli; P Giordani; P Muretto; G Catalano
Journal:  BMC Cancer       Date:  2001-08-01       Impact factor: 4.430

Review 5.  Comparison of the overall survival of proximal and distal gastric cancer after gastrectomy: a systematic review and meta-analysis.

Authors:  Jiaming Xue; Huiliang Yang; Shanshan Huang; Tingting Zhou; Xiangwen Zhang; Guo Zu
Journal:  World J Surg Oncol       Date:  2021-01-19       Impact factor: 2.754

Review 6.  One stomach, two subtypes of carcinoma-the differences between distal and proximal gastric cancer.

Authors:  Yuan Zhang; Peng-Shan Zhang; Ze-Yin Rong; Chen Huang
Journal:  Gastroenterol Rep (Oxf)       Date:  2021-11-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.